Figure 2.
Figure 2. BIRB 796 BS dose-dependently inhibits LPS-induced endothelial cell activation. Subjects received an intravenous injection of LPS (4 ng/kg) at 0 hours, preceded by oral ingestion of placebo (□), 50 mg BIRB 796 BS (○), or 600 mg BIRB 796 BS (▴) at – 3 hours. Left panel: sE-selectin; right panel: VWF. Data are the mean ± SEM. Asterisks indicate P value less than .05 versus placebo for the curve indicated, that is, high-dose BIRB 796 BS inhibited both VWF and sE-selectin (P < .05 vs placebo).

BIRB 796 BS dose-dependently inhibits LPS-induced endothelial cell activation. Subjects received an intravenous injection of LPS (4 ng/kg) at 0 hours, preceded by oral ingestion of placebo (□), 50 mg BIRB 796 BS (○), or 600 mg BIRB 796 BS (▴) at – 3 hours. Left panel: sE-selectin; right panel: VWF. Data are the mean ± SEM. Asterisks indicate P value less than .05 versus placebo for the curve indicated, that is, high-dose BIRB 796 BS inhibited both VWF and sE-selectin (P < .05 vs placebo).

Close Modal

or Create an Account

Close Modal
Close Modal